Summary. We assayed Epstein-Barr virus (EBV) antibody titers in patients' sera using indirect immunofluorescence and tested for the presence of antibody to EBV immediate-early BZLF1 protein ZEBRA by Western blotting to explore the association of EBV infection with uveitis. IgG and IgA antibodies to viral capsid antigen (VCA), IgG antibodies to early antigen (EA), and antibodies to EBV nuclear antigen were detected at higher titers in sera of patients with uveitis than in the sera of healthy controls. Neither IgM antibody to VCA nor EA was detected in the patients' sera. Anti-ZEBRA-IgG antibodies were detected in most patients' sera, but not in those of healthy controls. These results suggest that uveitis might be a disease accompanied by EBV reactivation.
Introduction
Here, we studied the association of Epstein-Barr virus (EBV) with uveitis (intraocular inflammation). Uveitis implies an inflammation primarily of the uveal tract. Also, such reactions occur in many systemic diseases, such as sarcoidosis, Behçet disease, and so on. An etiological classification of the inflammatory diseases of the uveal tract is a matter of considerable difficulty. The cause of many clinical conditions is disputed [11] . A cryptogenic uveitis is most common in the etiology of uveitis, and autoimmune disease is considered as one of the etiologies. It has also been suggested that EBV might be one of the etiologic factors in uveitis.
EBV causes infectious mononucleosis (IM) and is closely associated with Burkitt's lymphoma (BL) and nasopharyngeal carcinoma (NPC) as well as various malignant and non-malignant diseases [13] . Some autoimmune diseases are also associated with EBV infection: systemic lupus erythematosus (SLE) [8] , rheumatoid arthritis (RA) [5, 17] , multiple sclerosis (MS) [10] , and Sjögren's syndrome (SS) [6] . In ophthalmic diseases, EBV association has been reported in SS [12] and uveitis [15] ; in ophthalmic tissues, the expression of EBV receptor [9] and EBV genome [1] have been detected.
EBV-specific sero-diagnosis has been established by indirect immunofluorescence testing [13] . It is useful for the diagnosis of primary EBV infection and reactivation of EBV in patients. Diagnostic EBV antibodies are directed against: viral capsid antigen (VCA), with IgM antibody appearing transiently during the acute phase of IM; early antigen (EA)-and VCA, with IgG antibodies also arising during the acute phase; and EBV nuclear antigen (EBNA), with IgG antibodies appearing in the convalescent phase. Anti-VCA IgG and anti-EBNA antibodies are maintained throughout life. Antibodies to EA are detected in sera of patients with EBV-associated diseases but are also slightly detectable in sera of healthy subjects [4] .
The EBV immediate early gene BZLF1 (referred to as BamHI Z left open reading frame 1) encodes a protein termed ZEBRA (BamHI Z EBV replication activator). It transactivates other EBV immediate-early, early, and late genes [2] . ZEBRA plays an important role in EBV reactivation in B cells, and antibodies to ZEBRA are a specific marker for detecting the occurrence of EBV reactivation [14, 19] .
In this study, we measured EBV antibody titers and tested for ZEBRA-IgG antibodies in the sera of patients with uveitis. Our results demonstrate that EBV antibody titers in the patients are higher than those in healthy controls; ZEBRAIgG antibodies are detected in most patients' sera, but not in healthy controls' sera.
Materials and methods
This study was approved by the Medical Ethics Committee for Human Subject Research at the Faculty of Medicine, Tottori University. This study investigated sera from 19 (7 males and 12 females) patients (12-84 years old: 48.4 ± 20.3) with uveitis (Table 1) , and 20 (9 males and 11 females) healthy controls (24-80 years old: 45.3 ± 17.4). There were no statistically significant differences between patients and healthy controls in terms of age and gender (p>0.05). Sera were collected at the Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, from patients and healthy volunteers including employees and students. Of these patients, 16 were in acute phase and 3 were in remission phase; 7 patients had accompanying sarcoidosis, one had Behçet disease, and 11 patients were unclassified.
EBV antibody titers were assayed by the indirect immunofluorescence technique described previously [14, 19] . Briefly, IgG, IgA, and IgM antibodies to VCA were assayed in P3HR-1 cells, and IgG and IgM antibodies to EA were assayed in P3HR-1 EBV-superinfected Raji cells. These cells were smeared onto slides, fixed with acetone, and incubated with sera diluted with phosphate buffered saline (PBS) for 45 min at 37 • C. The reaction for detection of IgM antibodies was carried out for 3 h. After washing with PBS, the slides were incubated with FITC-conjugated anti-human IgG, IgA, or IgM antibody for 45 min at 37 • C. Antibodies to EBNA were assayed in Raji cells using anti-complement immunofluorescence.
The slides were chosen blindly and viewed by fluorescence microscopy. Initially, a 1:10 dilution of serum was screened; if the serum was positive in this dilution, a serial 2-fold dilution of serum was made and the titer was determined. The fluorescence intensity was graded from − to +++; the last serum dilution yielding + was taken as the end point and indicated as the antibody titer. For detection of antibodies to ZEBRA by Western blot analysis, ZEBRA was produced in Escherichia coli containing plasmid TrpE-BZLF1 (a gift from Dr. G. Miller, Yale University), prepared as described previously [14] . The protein was denatured in sample buffer (65 mM Tris-HCl [pH 6.8], 3% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.005% bromophenol blue) by boiling it for 10 min. Then it was applied to a 10% SDS-polyacrylamide gel and electrophoresed. The protein was transferred onto a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA) and incubated overnight in PBS-Tween 20 solution containing 5% nonfat dry milk powder for blocking at room temperature. The blots were incubated with diluted human sera at 1:640 dilution in PBS containing 0.05% Tween 20 (PBS/T) for 2 h. They were then incubated with anti-human IgG conjugated with alkaline phosphatase (Tago Immunologicals, Burlingame, CA) diluted 1:50,000 in PBS/T, followed by chemiluminescence reaction and exposure to X-ray film.
The antibody titers to herpes simplex virus (HSV), varicella-zoster virus (VZV), and cytomegalovirus (CMV) were assayed at a clinical diagnostic company (SRL. Inc, Tokyo, Japan). Antibody titers to HSV were assayed by a complement fixation test (CF) and a fluorescent antibody method (FA). Antibody titers to VZV were assayed by CF and enzyme immunoassay (EIA). CMV antibody titers were assayed by EIA.
Statistical analysis was done using a software application (Stat View for Macintosh; SAS Institute Inc., Cary, NC) on a Macintosh computer (Power Book 145B; Apple Computer Inc.). The statistical significance of GMTs and the ratio of high EBV antibody titers were analyzed by the Mann-Whitney U-test and the chi-square test, respectively.
Results
Antibodies to EA have been used as a diagnostic marker for EBV infectious diseases [13] . EA-IgG antibodies ( 1:10) were detected in 7/19 (36.8%) and in 4/20 (20.0%), respectively, of the patients' sera and the control sera (Fig. 1) . The geometric mean titers (GMTs) of patients and healthy controls were 1:3.4 and 1:1.6. The GMT of EA-IgG of patients was not significantly higher than that of healthy controls (P > 0.05). We did not detect EA-IgM antibodies in patients' sera or control sera (data not shown).
All uveitis patients' sera and control sera had anti-VCA-IgG antibody titers of 1:40 or higher. High VCA-IgG titers ( 1:640) were detected in 11/19 (57.9%) patients' sera; five sera from patients with uveitis showed extremely high values ( 1:1280). The VCA-IgG titers of healthy control sera were 1:40 to 1:1280, but most sera of healthy controls (17/20, 85.0%) were 1:320. The respective GMTs of patients and healthy controls were 1:480 and 1:220. The GMT of VCA-IgG of patients was significantly higher than that of healthy controls (P < 0.05).
It is noteworthy that the VCA-IgA titers ( 1:10) were detected in 17/19 (89.4%) of the patients' sera, whereas the titers were detected in 7/20 (35.0%) of healthy controls. The GMTs of VCA-IgA of patients and healthy controls were 1:30 and 1:2, respectively. The GMT of VCA-IgA of patients was significantly higher than that of healthy controls (P<0.0001). VCA-IgM antibody was not detected in patients' or controls' sera (data not shown).
All patients' and controls' sera had EBNA antibodies ( 1:10). The GMTs of EBNA of patients and healthy controls were 1:140 and 1:60, respectively. The GMT of EBNA of patients was significantly higher than that of healthy controls (P < 0.05). The EBV antibody titers overlapped in patients and healthy controls (Fig. 1) . Therefore, the prevalence of EBV antibody titers was evaluated using the ratio (%) of high EBV antibody titers (Fig. 2) . The antibody titers (EA-IgG 40, VCA-IgG 640, VCA-IgA 40 and EBNA 320) were above the normal ranges ( Fig. 1) [14] and chosen as the significant positive titers. EA-IgG antibodies ( 1:40) were found in 21.1% of patients with uveitis and 0% of healthy controls. The ratios in the patients were significantly higher than in healthy controls (P < 0.05). VCA-IgG antibody titers ( 1:640) were found in 57.9% and 15.0%, respectively, in the patients and healthy controls. The ratios in the patients were significantly higher than in healthy controls (P < 0.01). The VCA-IgA antibody titers ( 1:40) were 42.1% and 10.0%, respectively, in the patients and healthy controls. The EBNA antibody titers ( 1:320) were 42.1% and 10.0%, respectively, in the patients and healthy controls. These ratios were significantly higher in the patients than in healthy controls (P < 0.05).
ZEBRA is a marker of EBV reactivation in patients [14, 19] . The ZEBRA of Trp-BZLF1 plasmid was detected in a single molecule of 71 KDa by Western blotting. ZEBRA-IgG antibodies were detected in 20/23 (87.0%) of sera of patients who were in active or remission phase (Fig. 3) . Strong signals were seen in lanes 3 . Detection of ZEBRA-IgG antibodies in sera of patients with uveitis and healthy controls by immunoblotting. ZEBRA in a membrane filter was reacted with diluted sera (1:640) from healthy controls (1-10) and patients with uveitis (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Lanes (11 , 3 , 7 and 10 ) were collected 6-12 months later from the same patients (11, 3, 7 and 10) . ZEBRA was detected in a single molecule with 71 kDa by an anti-ZEBRA monoclonal antibody (lane P), but not by an EBV antibody negative human serum (N). The lanes (11, 12, 13, 7 and 10 ) were in remission phase #9, #17, and #19, and weak signals in other lanes. However, they were not detected in sera of healthy controls. These results indicate that EBV reactivation occurs in patients with uveitis in both the inflammation and remission phases. We assayed the antibody titers to other herpesviruses in several patients at early stages of this study. The results showed that antibody titers to HSV and VZV, but not CMV, slightly increased to standard values in some patients (Table 1) .
Discussion
We demonstrated that EBV antibody titers were elevated in sera of patients with uveitis. EA-IgG, VCA-IgG, VCA-IgA, and EBNA antibody titers were significantly elevated in the patients. ZEBRA-IgG antibodies, as a marker of EBV reactivation, were detected in 87.0% patients in the active and remission phases. Neither IgM antibodies to EA nor VCA were detected in the patients' sera. These results indicate that most patients, regardless of active and remission phases, have chronic, but not recent (acute), EBV infection.
High EBV antibody titers are observed in patients with EBV-associated malignant diseases, BL, NPC, Hodgkin's disease [13] , and gastric carcinoma [16] . In general, patients with EBV-associated diseases have high antibody titers to VCAIgG [11] . Also, chronic active EBV infections are categorized by extremely high titers of EBV antibodies [13] . These diseases are caused by uncontrolled outgrowth of EBV-infected T, B, and/or NK cells. Moderate EBV antibody titers, but higher than in healthy controls, are observed in some autoimmune and autoimmune-like diseases such as RA, SLE, and MS as well as chronic fatigue syndrome [14] . We assayed the antibody titers to HSV, VZV, and CMV in some patients and found a slight elevation of the antibody titers to HSV and VZV (Table 1 ). This result suggested that the elevation of EBV antibody titers in uveitis might be specifically associated with EBV reactivation.
High EBV antibody titers [13] and a high load of EBV genome in peripheral blood lymphocytes [17] reveal the association of EBV to diseases. Our results indicate close association between uveitis and EBV reactivation. We hypothesize the possibility of pathogenesis of EBV infection in patients with uveitis as follows:
As the first step, EBV-reactivated B cells might be trapped to the uvea, which contains abundant vessels, and EBV might infect and replicate in the pigment epithelium of the iris and ciliary body or retinal pigment epithelium. The infection might induce a cytopathogenic effect and inflammation of ocular tissues. This possibility is supported by evidence that the expression of the EBV receptor and EBV genome have been detected in intraocular tissues [18] . Our data demonstrate that ZEBRA-IgG antibodies, which are the EBV reactivation marker, were detected in sera of patients with uveitis. Since ZEBRA expression has been found in salivary gland epithelia from SS patients [6] , it is possible that ZEBRA might be expressed in the EBV-infected pigment epithelium.
High titers of VCA-IgA antibodies were detected in patients with uveitis. They are detected only in patients' sera with EBV-infected epithelial tumor NPC [3] and gastric carcinoma [16] , but not in healthy controls. It is believed that the tumors develop in intra-mucosal areas that might produce IgA antibodies. IgA antibodies play an important role in mucosal immunity, including ocular surface immunity for various pathogens. However, it is difficult to explain the relationship between IgA antibodies and intraocular inflammation, despite the elevation of VCA-IgA antibody titers in our data. In some uveitis patients, however, other mucosal tissues are involved in pathogenesis, such as upper respiratory and pulmonary involvement and lacrimal and salivary gland inflammation in sarcoidosis, and oral ulcer, genital ulcer, and gastrointestinal involvement in Behcet disease. Abundant VCA-IgA antibodies may be produced by mucosal immunity against these lesions. This fact can partly explain the elevation of the titers of VCA-IgA antibodies in uveitis, and the elevation of VCA-IgA in cases of intraocular inflammation alone indicates the possible existence of subclinical mucosal lesions in these cases.
As the second step, EBV infection in the pigment epithelium might expose or alter antigens in these tissues, or EBV reactivated-B cells could activate autoimmune reaction by molecular mimicry, and newly formed T lymphocytes against intraocular autoantigens or EBV-specific cytotoxic T lymphocytes might destroy non-infected uvea. Many reports describe the possibility of molecular mimicry in systemic disease related to EBV infection [5, 6, 8] . The putative mechanism for association of EBV infection and development of SLE is a cross-reaction between EBNA1 and Sm/nRNP [7] .
In conclusion, we have demonstrated that patients with uveitis attain high EBV antibody titers. We suggest that the uveitis is closely associated with EBV reactivation. To further elucidate whether EBV reactivation is the cause or the result of intraocular inflammation and to define the pathological roles of EBV on uveitis, including autoimmune mechanisms, EBV infection in patients' eyes and the EBV load in peripheral blood lymphocytes should be studied.
